CareLit · DOI-Nachweis · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease
DOI 10.1007/s00103-015-2253-z
Bibliografische Angaben
Nachweis in CareLit
Autor:innenHellenbrand, W.; Koch, J.; Harder, T.; Bogdan, C.; Heininger, U.; Tenenbaum, T.; Terhardt, M.; Vogel, U.; Wichmann, O.; von Kries, R.
ZeitschriftBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Ausgabe11/2015
Jahrgang / SeitenJg. 58 · S. 1314 bis 1343
Kernaussage aus der Literatur
Abstract-Vorschau
In December 2013 Bexsero® became available in Germany for vaccination against serogroup B meningococci (MenB). In August 2015 the German Standing Committee on Vaccination (STIKO) endorsed a recommendation for use of this vaccine in persons at increased risk of invasive meningococcal disease (IMD). This background paper summarizes the evidence underlying the recommendation. Bexsero® is based on surface protein antige…
Zitieren
Zitierempfehlung
Hellenbrand, W.; Koch, J.; Harder, T.; Bogdan, C.; Heininger, U.; Tenenbaum, T.; Terhardt, M.; Vogel, U.; Wichmann, O.; von Kries, R (2015) Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 58 (11), 1314 bis 1343. https://doi.org/10.1007/s00103-015-2253-z
Mit CareLit weiterarbeiten